Antibodies

02 Jun 2009 New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
02 Jun 2009 Investigational Antibody Treatment to Prevent C. difficile Recurrence Highlighted at Digestive Disease Week 2009
02 Jun 2009 Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential to Protect Against Newly Emerging Flu Strains with Pandemic Potential
01 Jun 2009 Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
31 May 2009 Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)
31 May 2009 Antisoma’s AS1409 shows anti-cancer activity in phase I trial
31 May 2009 Novel Targeted Radiation Therapy From Immunomedics Produces Objective Responses in Pancreatic Cancer
31 May 2009 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
30 May 2009 ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO
30 May 2009 Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab
30 May 2009 Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer
30 May 2009 Immunomedics Reports Updated Results of Milatuzumab in Dose-Escalation Study for Multiple Myeloma
29 May 2009 Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation
29 May 2009 Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advanced Breast Cancer
29 May 2009 FDA ADVISORY PANEL MAKES FAVORABLE RECOMMENDATION FOR GLAXOSMITHKLINE AND GENMAB’S ARZERRA™ (OFATUMUMAB)
28 May 2009 Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
27 May 2009 Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
26 May 2009 FDA Extends Review Timeline for STELARA™ (Ustekinumab) Biologic License Application by Three Months
25 May 2009 Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
21 May 2009 Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
21 May 2009 Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
20 May 2009 Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
18 May 2009 Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
15 May 2009 GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
14 May 2009 UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top